Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment further demonstrating our philosophy that investments in companies should positively impact the health and well-being of patients.
Main areas of scientific interest
Forbion contributes to the health and well-being of patients worldwide. Our companies have positively affected almost half a million patients in the areas of:
Life Sciences
- Autoimmune & Inflammation
- Cardiovascular/Metabolic
- Central nervous system
- Digestive & Renal
- Oncology
- Ophthamology
- Orphan/rare disease
- Respiratory
BioEconomy
- Food
- Agriculture
- Materials
- Environmental Technologies
Forbion then and now
Forbion was born out of ABN AMRO Capital Life Sciences. Today, to emphasize its value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits.
Forbion currently manages €3 bn across nine funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees.
Forbion’s investors include the European Investment Fund (EIF), notably through its European Recovery Programme (ERP), LfA, the Dutch Venture Initiative (DVI) and AMUF facilities, and the Kreditanstalt für Wiederaufbau (KFW) through the ERP – Venture Capital Fondsfinanzierung facility.
- € 3bn across 9 funds
- € 750m Forbion Ventures VI
- € 600m Forbion Growth Opportunities Fund II
- 43 active portfolio companies